A novel antienterococcal peptide was prepared by fusing the enterococcal cCF10 pheromone to the channelforming domain of colicin Ia, forming Enterococcus faecalis pheromonicin (PMC-EF). This peptide was bactericidal against vancomycin-resistant Enterococcus faecalis (VRE) organisms. Electron microscopy and vital dyes confirmed increased membrane permeability. All mice made bacteremic with VRE strains survived when they were treated with PMC-EF, while all controls died.
A major problem in the treatment of bacterial infections has been the emergence of antibiotic resistance. This is true for Enterococcus faecium and to a lesser extent for Enterococcus faecalis, which have developed resistance to many antibiotics, including vancomycin (12, 16) . We have shown that a staphylococcal pheromone fused to a channel-forming peptide killed staphylococci in culture and animal infections (14) . Here, we report on an application of that strategy to vancomycin-resistant E. faecalis (VRE) strains.
Escherichia coli cells can secrete colicins, which possess channel-forming properties bactericidal only to E. coli. Colicin Ia introduces a lethal 175-residue C-terminal channel into cell membranes of targeted E. coli (6, 8, 10, 13, 15, 17) . Our plan was to fuse the C terminus of colicin Ia to cCF10, a 7-residue pheromone produced by enterococci (2, 8) . This pheromone traverses recipient cell walls and interacts with a corresponding prgZ component of the cell membrane (1, 3, 4) .
Mutagenesis of PMC-EF. We constructed the LVTLVFV amino acid sequence of pheromone cCF10 to follow position I626 of colicin Ia by double-stranded oligonucleotide mutagenesis (QuickChange kit; Stratagene) by using a Promega pSELECT-1 plasmid containing the colicin Ia gene (P. Gosh, University of California at San Francisco) to form E. faecalis pheromonicin (PMC-EF). We used the 5Ј-3Ј oligonucleotide containing the desired LVTLVFV mutation (in bold) GCGAATAAGTT CTGGGGTATTCTGGTTACCCTTGTGTCCGTGTAAAT AAAATATAAGACAGGC. Controls consisted of a random peptide of the same length as cCF10 and an unrelated staphylococcal pheromone fused at the N terminus instead of the C terminus (reversed PMC-EF) ( Fig. 1a ). Plasmids were transfected into TG1 E. coli cells and purified (7, 9) .
In vitro bactericidal assays. We grew vancomycin-sensitive E. faecalis ATCC 29212 and vancomycin-resistant E. faecalis ATCC 700802 (American Type Culture Collection, Manassas, Va.) as described previously (3) . Shenyang Biotechnic Co. (Shanghai, People's Republic of China) synthesized cCF10.
Wild-type colicin Ia from TG1 cells transfected with colicin Ia plasmid, PMC-EF from TG1 cells transfected with reversed PMC-EF, a random protein with an SMTTVGG peptide introduced at the C terminus of colicin Ia, penicillin, and vancomycin served as controls. Turbidimetric measurements and colony counting were performed (5) .
Electron microscopy and immunolabeling. We incubated VRE cells with PMC-EF, vancomycin, or growth medium alone for 2 h, then stained them with 1% phosphotungstic acid, and observed them under an electron microscope (Jeol JEM-100SX; Jeol, Akishima, Japan) at a magnification of ϫ15,000 to ϫ40,000.
We incubated VRE and BAA-42 methicillin-resistant Staphylococcus aureus cells with PMC-EF, PMC-EF plus free cCF10, vancomycin, or growth medium alone for 40 min, then fixed the cells in phosphate-buffered saline-paraformaldehyde, incubated specimens with rabbit anti-colicin Ia antibody (1:10 in 3% skim milk) (Babco Berkeley Antibody Co., Richmond, Calif.) followed by goat anti-rabbit antibody labeled with 5-nmdiameter gold particles (1:100 in 3% skim milk) (Wuhan Boster Biol. Tech. Co., Wuhan, People's Republic of China), and fixed the cells in phosphate-buffered saline-glutaraldehyde. Specimens were fixed in OsO 4 and embedded in Epon 812. Ultrathin sections were stained with uranyl acetate and lead citrate and then observed with a Hitachi H-600 electron microscope at 80 kV (11) .
The domains of the fusion peptide PMC-EF are shown in Fig. 1a and b. Figure 1c shows a polyacrylamide gel of the enterococcal chimeric protein PMC-EF (Fig. 1c, lane 2) and a control chimeric protein containing pheromone from S. aureus (PMC-SA) (Fig. 1c, lane 3) .
Exposure of E. faecalis ATCC 29212 nonresistant cells to PMC-EF inhibited growth by 90% ( Fig. 2a ), while penicillin G inhibited growth by 80%. Control peptides with an unrelated 8-residue staphylococcal pheromone or a random 7-residue peptide linked at the C terminus of colicin Ia had no effects. Vancomycin (5 g/ml) slowed initial growth of VRE cells (Fig.  2b) . However, later there was no significant difference compared to untreated controls. In contrast, 5 g of PMC-EF/ml inhibited VRE cell growth by 85%. Addition of free cCF10 pheromone (Fig. 2c ) blocked PMC-EF inhibition of VRE cell growth in a concentration-dependent manner. Incubation of VRE with either free cCF10 or wild-type colicin Ia alone (Fig.  2d ) did not inhibit cell growth. In contrast, PMC-EF resulted in less than 10% growth inhibition when administered to S. aureus or Streptococcus pneumoniae ( Fig. 2e and f) . Exposure of S. aureus cells to PMC-SA, a control chimeric protein containing pheromone from S. aureus, caused an 80% growth inhibition ( Fig. 2e) (14) . Withdrawal of PMC-EF failed to restore growth (data not shown).
Electron microscopy of VRE cells incubated with vancomycin (Fig. 3b ) showed a morphological appearance like that of untreated cells (Fig. 3a) . In contrast, after incubation with PMC-EF, 60% of VRE cells per field were distorted ( Fig. 3c and d) (less than 7% per field were distorted in controls). Free cCF10 blocked adsorption of gold-labeled antibody on cytoplasmic membranes of enterococcal cells treated with PMC-EF ( Fig. 3h ). As shown in Fig. 3f and g, some VRE cells exposed to PMC-EF developed ruptured cell walls.
Initially after exposure to PMC-EF (Fig. 4a ), the number of VRE cells stained (green) by fluorescein isothiocyanate (FITC)-labeled antibody exceeded that stained (red) with propidium iodide, a vital dye. The ratio of red to green VRE cells increased with time ( Fig. 4a to d) . The number of dual-labeled cells increased to a maximum at 0.5 h (Fig. 4b ) and then declined, while cells with propidium iodide staining decreased, and FITC staining was almost absent by 2 h (Fig. 4d ). There was no significant propidium staining and no FITC labeling of untreated cells (Fig. 4e to h) .
In a mouse VRE sepsis model, all mice treated with PMC-EF survived, while all untreated mice died within 3 days. None of the E. faecalis-infected mice survived with vancomycin (data not shown). The emergence of vancomycin-resistant enterococci has been the result of increased use of vancomycin in enterococcal infections (12, 16) . In addition, conjugal transfer of the vanA operon from enterococci has resulted in vancomycin resistance in other bacteria (12, 16) . Multidrug resistance is now common among those pathogens (12, 16) . Successful treatment of antibiotic-resistant bacteria will require novel agents whose mechanisms of action are different from those of conventional agents.
We conclude that a chimeric peptide containing pheromone and channel-forming domains can be targeted to antibiotic-resistant bacteria, resulting in substantial bactericidal effects. Furthermore, because a variety of pheromones are known, fusion peptides could be tailored to particular bacteria and provide novel "narrow-spectrum" antibiotics. 
